Literature DB >> 7975222

Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid.

M Cotten1, M Saltik, M Kursa, E Wagner, G Maass, M L Birnstiel.   

Abstract

Adenovirus entry into its host cell transiently permeabilizes the cell allowing the coentry of reagents such as DNA. We compare here adenovirus inactivation with beta-propiolactone and several psoralen derivatives, seeking reagents that disrupt the viral genome without impairing the viral entry functions. No virus replication can be detected after 8-methoxypsoralen (8-MOP) modification. Viral transcription is not detectable by Northern analysis, and reverse transcriptase/PCR analysis demonstrates at least a 1000-fold decrease in viral transcription after 8-MOP treatment. Using [3H]8-MOP, the psoralen is found to enter the virus capsid and react throughout the viral genome, with approximately one psoralen modification per 100 bp of viral DNA. This inactivated adenovirus allows us to deliver DNA to target cells without interference from adenovirus gene expression or replication. Furthermore, we can now study the host cell response to adenovirus entry without the complications of adenovirus gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975222     DOI: 10.1006/viro.1994.1641

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases.

Authors:  C E Thomas; G Schiedner; S Kochanek; M G Castro; P R Löwenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  Exploiting features of adenovirus replication to support mammalian kinase production.

Authors:  Matt Cotten; Kerstin Stegmueller; Jan Eickhoff; Miriam Hanke; Katrin Herzberger; Thomas Herget; Axel Choidas; Henrik Daub; Klaus Godl
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

3.  Extrachromosomal recombination occurs efficiently in cells defective in various DNA repair systems.

Authors:  C Morrison; E Wagner
Journal:  Nucleic Acids Res       Date:  1996-06-01       Impact factor: 16.971

4.  Sensing adenovirus infection: activation of interferon regulatory factor 3 in RAW 264.7 cells.

Authors:  Saskia C Stein; Erik Falck-Pedersen
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Akt/protein kinase B activation by adenovirus vectors contributes to NFkappaB-dependent CXCL10 expression.

Authors:  Qiang Liu; Lindsay R White; Sharon A Clark; Daniel J Heffner; Brent W Winston; Lee Anne Tibbles; Daniel A Muruve
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10.

Authors:  Lee Anne Tibbles; Jason C L Spurrell; Gloria P Bowen; Qiang Liu; Mindy Lam; Anne K Zaiss; Stephen M Robbins; Morley D Hollenberg; Thomas J Wickham; Daniel A Muruve
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Analysis of human cytomegalovirus oriLyt sequence requirements in the context of the viral genome.

Authors:  Eva-Maria Borst; Martin Messerle
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

Authors:  T Kafri; D Morgan; T Krahl; N Sarvetnick; L Sherman; I Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

9.  Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors.

Authors:  Y Ilan; R Prakash; A Davidson; G Droguett; M S Horwitz; N R Chowdhury; J R Chowdhury
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

10.  Controlled inactivation of recombinant viruses with vitamin B2.

Authors:  Shellie M Callahan; Piyanuch Wonganan; Linda J Obenauer-Kutner; Suganto Sutjipto; Joseph D Dekker; Maria A Croyle
Journal:  J Virol Methods       Date:  2007-12-21       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.